In a Phase III study administering sub-therapeutic doses of rifabutin in combination therapy to patients not identified with Mycobacterium avium paratuberculosis (MAP) infections, it was associated with significant short term benefits.
In a Phase III trial, administering sub-therapeutic doses of rifabutin in combination therapy to patients without confirmed Mycobacterium avium paratuberculosis (MAP) infections resulted in notable short-term benefits.